How to Get Leqvio (Inclisiran) in Wisconsin

What Is Leqvio and Why Is It Prescribed?

Leqvio (inclisiran) is a small interfering RNA (siRNA) that silences PCSK9 messenger RNA in hepatocytes, reducing LDL-C by roughly 50% with only two injections per year after the loading phase. The FDA approved it on December 22, 2021, for adults with established atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who need additional LDL lowering on top of maximally tolerated statin therapy. [1]

The mechanism differs from monoclonal antibody PCSK9 inhibitors like evolocumab (Repatha) and alirocumab (Praluent). Rather than blocking the PCSK9 protein after it is made, inclisiran prevents the liver from producing it in the first place. This upstream action produces durable, twice-yearly LDL suppression without the need for monthly self-injections. [2]

ORION-10 (N=1,561, U.S. patients with ASCVD) and ORION-11 (N=1,617, ASCVD or ASCVD-risk equivalents) demonstrated this durability clearly. At 510 days, inclisiran 284 mg reduced LDL-C by 52.3% and 49.9% from baseline versus placebo, respectively, with P<0.001 for both trials. [3] These two phase 3 trials, published together in the New England Journal of Medicine in 2020, form the backbone of every major prescribing guideline that now includes inclisiran. [3]

The 2022 ACC Expert Consensus Decision Pathway on Non-Statin Therapies states: "Inclisiran is a reasonable addition to maximally tolerated statin therapy when LDL-C remains above goal in patients with ASCVD or HeFH." [4] For Wisconsin patients already on high-intensity statins who have not reached their LDL target of <70 mg/dL (ASCVD) or <100 mg/dL (HeFH), inclisiran is a guideline-supported next step.

Who Qualifies for Leqvio in Wisconsin?

Qualification hinges on three criteria: diagnosis, LDL threshold, and statin history. Adults with established ASCVD (prior MI, stroke, or symptomatic peripheral arterial disease) or confirmed HeFH are the FDA-approved population. [1] Wisconsin Medicaid (ForwardHealth) covers inclisiran with prior authorization when the patient carries one of these diagnoses and has documented intolerance or inadequate response to maximally tolerated statin therapy. [5]

LDL thresholds for PA approval vary by insurer, but most Wisconsin commercial carriers align with the ACC/AHA 2019 Guideline on the Management of Blood Cholesterol, which recommends considering non-statin add-on therapy when LDL-C remains at or above 70 mg/dL in very-high-risk ASCVD patients despite maximal statin and ezetimibe use. [6] Some Wisconsin plans additionally require a trial of ezetimibe before approving inclisiran, so documenting ezetimibe use or intolerance is advisable. [6]

HeFH diagnosis may be established via the Dutch Lipid Clinic Network criteria, genetic testing showing a pathogenic LDL receptor mutation, or a clinical score. The CDC estimates that HeFH affects approximately 1 in 250 people in the United States, which means roughly 23,000 Wisconsin residents may carry the diagnosis. [7] Most remain undiagnosed, and inclisiran offers a viable treatment path once HeFH is confirmed.

Labs and Workup Required Before Starting Leqvio

A standard lipid panel is the minimum requirement before any prescriber in Wisconsin can write for inclisiran. Several payers and the FDA label also recommend baseline hepatic function tests, since inclisiran is metabolized in the liver. [1]

The specific pre-treatment workup typically includes: a fasting lipid panel drawn within 90 days of the prescription request, a comprehensive metabolic panel (CMP) to document liver enzymes and renal function, and, if HeFH is the indication, documentation of the diagnostic criteria used. [8] Genetic testing for LDLR, APOB, or PCSK9 mutations strengthens a HeFH prior authorization but is not always required. [8]

Wisconsin telehealth providers can order labs through national networks such as LabCorp or Quest, or through local Wisconsin health systems including Froedtert, UW Health, and Advocate Aurora. Results are reviewed asynchronously or during a synchronous video visit before the prescription is finalized. [9] Providers should note that inclisiran does not require routine monitoring labs after initiation, which reduces the burden of follow-up compared to some other lipid-lowering agents.

Renal impairment does not require dose adjustment; ORION-7 showed that inclisiran 300 mg produced similar PCSK9 reduction in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) compared to those with normal renal function. [10] That finding is relevant for Wisconsin patients with chronic kidney disease who also carry elevated cardiovascular risk.

How to Get a Leqvio Prescription in Wisconsin

Step 1: Choose an In-Person or Telehealth Prescriber

Wisconsin permits prescribing via synchronous audiovisual telemedicine under Wis. Stat. § 448.9725 and the Wisconsin Medical Examining Board's telemedicine guidance, provided the prescriber holds an active Wisconsin license or a recognized multi-state compact privilege. [11] This means a board-certified cardiologist, clinical lipidologist, endocrinologist, or internal medicine physician practicing via telehealth can legally prescribe inclisiran to a Wisconsin patient without an initial in-person visit, provided a sufficient clinical evaluation is conducted by video.

Nurse practitioners (NPs) and physician assistants (PAs) may also prescribe inclisiran in Wisconsin under their respective collaborative practice frameworks. Wisconsin NPs operate under collaborative agreements with physicians unless they qualify for independent practice status under state law. [11] PAs prescribe under a defined scope of practice with physician supervision. Both designations are legally authorized to prescribe Schedule-exempt medications including inclisiran.

Step 2: Complete the Prior Authorization

Prior authorization (PA) is required by most Wisconsin commercial plans and by ForwardHealth (Wisconsin Medicaid). The PA packet generally requires: [5]

• Current LDL-C lab value (most plans require LDL <70 mg/dL threshold not met)
• Diagnosis code (ICD-10 I25.10 for ASCVD, E78.01 for HeFH)
• Documentation of high-intensity statin use at maximally tolerated dose for at least 90 days
• Documentation of ezetimibe trial or contraindication, depending on the plan
• Attestation that the patient is an adult (age 18 or older per FDA label) [1]

PA processing typically takes 3 to 14 business days for commercial payers in Wisconsin. ForwardHealth PA decisions may take up to 21 days. Urgent PA requests can be expedited to 72 hours if the prescriber documents clinical urgency. [5]

Step 3: Drug Procurement and Administration

Leqvio is not dispensed at retail pharmacies in the traditional sense. Novartis uses a buy-and-bill model through specialty distributors and physician offices, or a limited distribution through specialty pharmacies. The prescriber's office orders the drug, stocks it, and administers it as an in-office injection. [1] This is a key logistical distinction for Wisconsin patients who expect to pick up a vial at a local Walgreens or CVS.

For telehealth-only patients who do not have an affiliated in-person clinic, the telehealth provider typically coordinates with a local Wisconsin cardiologist, primary care practice, or infusion center to administer the injection. This coordination step adds time but does not require the patient to switch prescribers.

The HealthRX Wisconsin Access Framework for inclisiran maps the typical patient pathway as follows: telehealth consult and lab review (days 1 to 7), prior authorization submission (days 7 to 10), PA decision (days 10 to 24), drug procurement by administering clinic (days 24 to 30), and first injection (approximately day 30 to 42). Patients with urgent cardiovascular need may compress this to 2 weeks through expedited PA and same-day clinic scheduling.

Leqvio Telehealth Options in Wisconsin

Several national telehealth platforms hold Wisconsin prescribing licenses and list inclisiran among their cardiovascular formulary. Patients searching for a "wisconsin leqvio doctor online" should verify that the platform employs physicians or NPs with active Wisconsin licenses, not merely national licenses, since Wisconsin requires a Wisconsin-specific license or compact privilege for telemedicine prescribing. [11]

During a telehealth visit for inclisiran, the clinician will review prior lipid panels, current medications (particularly statins and ezetimibe), cardiovascular history, and any documented statin intolerance. The 2019 ACC/AHA guideline defines statin intolerance as the inability to tolerate two or more statins, including one at the lowest starting dose, due to skeletal muscle or other adverse effects. [6] Telehealth platforms that conduct this level of structured intake can build a PA-ready chart on the first visit, reducing total time to prescription.

Asynchronous telemedicine (store-and-forward), where the patient submits records and answers questions without a live video call, may also be legally used in Wisconsin for follow-up visits after the initial synchronous evaluation. [11] This flexibility is useful for Wisconsin patients in rural areas, including those in the Northwoods and the Western Coulee and Ridges region, where driving to a cardiologist may involve 60 or more miles.

Wisconsin Medicaid and Commercial Insurance Coverage

Wisconsin Medicaid (ForwardHealth) covers inclisiran under the preferred drug list with prior authorization for both ASCVD and HeFH indications. [5] The PA criteria mirror the FDA label and require demonstration of inadequate LDL control on maximally tolerated statin. The annual cost of Leqvio without insurance exceeds $40,000, making coverage approval non-optional for nearly all patients. [12]

For commercially insured Wisconsin patients, the Novartis co-pay assistance program (Leqvio Together) can reduce out-of-pocket costs to as low as $0 per injection for eligible patients, provided they are not on a government plan. [12] Patients on Medicare Part B may have the drug covered under the medical benefit (not pharmacy benefit) since it is administered in a physician's office, subject to 20% coinsurance after the deductible. [13]

Medicare Part D does not typically cover inclisiran because the drug is classified as a physician-administered drug under Part B. Wisconsin Medicare Advantage plans may vary in their Part B drug coverage rules, and patients should verify this detail with their specific plan before the prescriber submits a PA. [13]

The American College of Cardiology notes that PCSK9-targeted therapies including inclisiran remain underutilized largely due to access barriers including prior authorization complexity. [4] For Wisconsin patients, the most common PA denial reasons are: insufficient statin trial documentation, missing ezetimibe step therapy, and LDL not documented above threshold at the time of the request.

503A Compounding of Inclisiran in Wisconsin

Wisconsin 503A pharmacies (traditional compounding pharmacies operating under state pharmacy board oversight) may compound inclisiran when a prescriber provides a valid patient-specific prescription and a documented medical need that cannot be met by the commercially available product. [14] The FDA has not placed inclisiran on its List of Drugs that Cannot Be Compounded, but 503A compounders must use bulk active pharmaceutical ingredient (API) sourced from an FDA-registered supplier. [14]

Compounding inclisiran at the 503A level is not common practice as of 2025, primarily because the commercial product is available and the mechanism requires precise siRNA stability handling. Patients considering compounded inclisiran should confirm that the 503A pharmacy holds an active Wisconsin Pharmacy Examining Board license and can document API sourcing and potency testing. [15]

503B outsourcing facilities, which operate under cGMP standards and supply healthcare facilities rather than individual patients, represent a separate pathway not typically applicable to individual Wisconsin patients. [14]

Transferring an Existing Leqvio Prescription to Wisconsin

A patient relocating to Wisconsin who already has an established inclisiran regimen can transfer care in one of two ways. The simplest path is for the new Wisconsin-licensed prescriber to review prior records and issue a new prescription under their license, since inclisiran has no DEA schedule and transfer restrictions are administrative rather than legal. [1]

The administering clinic in Wisconsin will need to obtain the drug through its own distributor account, which may require 1 to 3 weeks if the clinic has not previously stocked inclisiran. Patients transferring mid-cycle, meaning between their 90-day loading dose and their 6-month maintenance dose, should flag their injection schedule to the new provider so timing is preserved. Missing the 6-month window by more than 3 months may require restarting the loading protocol, per the Leqvio prescribing information. [1]

Insurance coverage does not automatically transfer when a patient moves to Wisconsin. A new PA under the Wisconsin plan will be required, and the process described above applies in full.

Efficacy Data Wisconsin Prescribers Rely On

The ORION-11 trial (N=1,617) enrolled patients with ASCVD or ASCVD risk equivalents across the U.S. and Europe and showed a time-averaged LDL-C reduction of 49.9% at day 510 for inclisiran versus a 0.8% increase in the placebo arm, with P<0.001. [3] Injection-site reactions occurred in 4.7% of inclisiran patients versus 0.5% of placebo patients but were predominantly mild and did not lead to discontinuation. [3]

ORION-10 (N=1,561), conducted exclusively in the United States, achieved a 52.3% time-averaged LDL-C reduction at day 510, also with P<0.001. [3] The consistent 50% LDL reduction across populations is one reason Wisconsin lipidologists and cardiologists have added inclisiran to their formulary for patients who cannot or will not self-inject monthly medications.

Longer-term data from the ORION-3 open-label extension study showed sustained LDL-C reductions at 4 years, with a mean reduction of 44.3% from baseline, confirming that the twice-yearly regimen maintains efficacy without apparent tachyphylaxis. [16] This durability is especially relevant for Wisconsin patients with poor medication adherence history, since missing a single injection does not erase progress the way missing daily oral statins can. [16]

The VICTORION-2P trial, a cardiovascular outcomes study, is ongoing as of mid-2025 and will provide definitive data on whether inclisiran reduces MACE (major adverse cardiovascular events) independently of LDL lowering. [17] Prescribers in Wisconsin should note that inclisiran's FDA approval is currently based on LDL surrogate endpoints, not completed cardiovascular outcomes data, a distinction the ACC Expert Consensus document also acknowledges. [4]

Safety Profile and Contraindications

Inclisiran carries no absolute contraindications other than documented hypersensitivity to the active substance or excipients. [1] The most common adverse event is injection-site reaction, occurring in roughly 5% of patients. [3] Unlike statins, inclisiran does not cause myopathy or raise creatine kinase, making it a strong option for patients with documented statin-related muscle symptoms. [8]

Hepatic transaminase elevations were not significantly different between inclisiran and placebo arms in ORION-10 and ORION-11, but baseline liver function documentation remains standard practice. [3] Pregnancy and lactation safety has not been established; inclisiran should not be used in patients who are pregnant or planning pregnancy. [1]

Drug interactions are minimal. Inclisiran is not metabolized by CYP450 enzymes and does not inhibit or induce them. [1] This pharmacological profile makes it suitable for Wisconsin patients on complex polypharmacy regimens typical of advanced cardiovascular disease, including anticoagulants, antiplatelets, and antihypertensives.